Recent events
Recent events tied to this brand in public sources.
Back to profile26 entries · Page 1 of 2
2021
Cipla acquires up to 33% interest in Clean Max Auriga Power
Cipla announced that it had acquired up to a 33% partnership interest in Clean Max Auriga Power LLP, which is engaged in renewable energy generation and supply.
2021
Cipla partners with Clensta for waterless technology products
Cipla partnered with Clensta International to market and distribute Clensta's waterless technology products. Cipla said it would conduct a marketing drive to educate prospective buyers.
2021
Clensta announced an extension of its partnership with Cipla
Clensta International announced an extension of its marketing and distribution partnership with Cipla for Clensta's waterless technology products.
2021
Cipla recalls 7,228 bottles of Solifenacin Succinate tablets in the US
Cipla initiated a US recall of 7,228 bottles of 10 mg, 30-count Solifenacin Succinate tablets because of current good manufacturing practices deviations. The USFDA classified it as a Class II recall.
2021
Cipla announces ViraGen test kit launch
Cipla announced that it would market and distribute its ViraGen COVID-19 RT-PCR test kit in India starting May 25, 2021; the kit had been approved by the Indian Council of Medical Research.
2021
Cipla and Ubio Technologies partner on COVID-19 test kit
Cipla teamed up with Ubio Technologies Biotechnology Systems to launch the ViraGen COVID-19 RT-PCR test kit in India.
2021
Cipla signs baricitinib licensing agreement with Eli Lilly
Cipla announced that it signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly for the manufacture and commercialization of baricitinib for COVID-19 in India.
2021
Cipla and SIGA announce strategic partnership
Cipla and SIGA Technologies announced a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against biothreats.
2021
Cipla Gulf expands biosimilar partnership with Alvotech
Cipla announced that its subsidiary Cipla Gulf was expanding its partnership with Alvotech to commercialize and distribute four biosimilar medicines in Australia and New Zealand. Alvotech develops and manufactures the products, and Cipla Gulf handles commercialization and distribution.
2020
Cipla recalls esomeprazole packets in the US
Cipla initiated a US recall of more than 580,000 packets of esomeprazole magnesium delayed-release oral suspension after the USFDA cited cross-contamination with theophylline. The USFDA classified it as a Class II recall.
2020
Cipla partners with Premier Medical Corporation to commercialize CIPtest
Cipla announced a partnership with Premier Medical Corporation to commercialize COVID-19 rapid antigen test kits in India. Cipla will market and distribute the test, which Premier Medical Corporation will manufacture; supply was scheduled to commence that week.
2020
Cipla settles blood cancer drug litigation with Bristol Myers
Cipla settled blood cancer drug litigation with Bristol Myers in the United States. The parties would file consent judgments with the U.S. District Court for New Jersey.
2020
Cipla and Celgene settle Revlimid patent litigation
Cipla announced a settlement of its patent litigation with Celgene concerning Revlimid. The settlement provides for consent judgments enjoining Cipla from marketing generic lenalidomide before the relevant patents expire, subject to settlement terms, and licenses for certain volume-limited US sales after a confidential date following March 2022 and unlimited sales no earlier than January 31, 2026. Cipla’s ability to market the drug is contingent on obtaining ANDA approval.
2020
Cipla announces ELIFast COVID-19 antibody test kits in India
Cipla announced the commercialisation in India of COVID-19 antibody detection kits marketed under the ELIFast brand. KARWA will manufacture the kits, while Cipla will handle marketing and distribution.
2020
Cipla and Boehringer Ingelheim India announce co-marketing partnership
Cipla and Boehringer Ingelheim India announced a partnership in India to co-market three oral anti-diabetic drugs: Oboravo, Oboravo Met and Tiptengio.
2020
Cipla launches Cipremi antiviral drug
Cipla launched Cipremi, an antiviral drug for treating COVID-19 patients, in India.
2020
Cipla and Roche Pharma India expand medicines distribution partnership
Cipla and Roche Products (India), known as Roche Pharma, announced an agreement under which Cipla will market and distribute Roche Pharma’s three named oncology medicines in India.
2020
Cipla signs non-exclusive Remdesivir license with Gilead Sciences
Cipla signed a non-exclusive licensing agreement with Gilead Sciences to manufacture and distribute Remdesivir. The agreement permits Cipla to manufacture the active pharmaceutical ingredient and finished product and market them in 127 countries, including India and South Africa.
2020
Cipla acquires four Wanbury nutrition brands
Cipla announced that it acquired four brands—CPink, CDense, Productiv and Folinine—from Wanbury's nutrition products portfolio to strengthen its presence in women's health.
2020
Cipla acquires Wanbury nutrition portfolio
Cipla announced that it had acquired Wanbury Ltd.'s nutrition products portfolio, including the brands CPink, CDense, Productiv and Folinine, to strengthen its presence in women's health.